Clinical

British Journal of Cancer (2003) 89, 1155–1158. doi:10.1038/sj.bjc.6601237 www.bjcancer.com
Published online 30 September 2003

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

M S Braun1, F Adab2, C Bradley3, K McAdam4, G Thomas5, N J Wadd6, D Rea7, R Philips8, C Twelves9, J Bozzino10, C MacMillan11, M P Saunders12, R Counsell13, H Anderson12, A McDonald9, J Stewart11, A Robinson14, S Davies1, F J Richards1 and M T Seymour1

  1. 1Cancer Research UK Centre in Leeds, Cookridge Hospital, Leeds LS16 6QB, UK
  2. 2Staffordshire Oncology Centre, Royal Infirmary, Princes Road, Hartshill, Stoke on Trent ST4 7LN, UK
  3. 3Department of Oncology, Bradford Royal Infirmary, Duckworth Lane, Bradford BD9 6RJ, UK
  4. 4Department of Clinical Oncology, Peterborough District Hospital, Thorpe Road, Peterborough, PE3 6DA, UK
  5. 5Department of Oncology, Derbyshire Royal Infirmary, London Road, Derby DE1 2QY, UK
  6. 6Department of Oncology, South Cleveland Hospital, Marton Road, Middlesbrough TS4 3BW, UK
  7. 7CRC Institute for Cancer Studies, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
  8. 8Department of Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK
  9. 9Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, UK
  10. 10Northern Centre for Cancer Treatment, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, UK
  11. 11Northamptonshire Centre for Oncology, Northampton General Hospital, Biling Road, Northampton NN1 5BD, UK
  12. 12Christie Hospital, Wilmslow Road, Withington, Manchester M20 4BX, UK
  13. 13Gloucestershire Oncology Centre, Cheltenham Royal Infirmary, Sandford Road, Cheltenham GL53 7AN, UK
  14. 14Department of Oncology, Southend Hospital, Westcliffe-on-Sea, Essex SS0 0RY, UK

Correspondence: Dr M Seymour, Cookridge Hospital, Leeds LS16 6QB, UK. E-mail: Matt.Seymour@leedsth.nhs.uk

Received 23 January 2003; Revised 23 May 2003; Accepted 29 June 2003.

Top

Abstract

We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.

Keywords:

fluorouracil, oxaliplatin, colorectal carcinoma